黏液活性药物在囊性纤维化中的应用：意大利专家的共识调查
Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists.
作者信息
Volpi Sonia, Carnovale Vincenzo, Colombo Carla, Raia Valeria, Blasi Francesco, Pappagallo Giovanni
机构信息
Cystic Fibrosis Center Azienda Ospedialiera Universitaria Integrata Verona Italy.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Cystic Fibrosis Center Milan Italy.
出版信息
Health Sci Rep. 2022 Jun 6;5(4):e604. doi: 10.1002/hsr2.604. eCollection 2022 Jul.
BACKGROUND
The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient's lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriateness of therapeutic use of dornase alfa (rhDNase) for CF patients.
METHOD
A consensus on appropriate prescribing in CF mucoactive agents was appraised by an online Delphi method, based on a panel of 27 pulmonologists, coordinated by a Scientific Committee of six experts in medical care of patients with CF.
RESULTS
Full or very high consensus was reached on several issues related to therapeutic use of dornase alfa for CF patients in clinical practice.
CONCLUSIONS
The consensus reached on a number of topics regarding use of mucoactive agents in patients with CF can help guide clinicians in daily practice based on expert experience and define the most appropriate therapeutic strategy for the individual patient.
背景
囊性纤维化（CF）黏液活性疗法的目标是提高痰液清除率，并减少患者一生中肺功能的渐进性下降。我们旨在调查意大利CF中心的专家对CF患者使用多纳培南（重组人脱氧核糖核酸酶）治疗的适宜性的共识程度。
方法
基于由6名CF患者医疗护理专家组成的科学委员会协调的27名肺科医生小组，通过在线德尔菲法评估CF黏液活性药物合理处方的共识。
结果
在临床实践中，对于CF患者使用多纳培南治疗的若干问题达成了完全或高度共识。
结论
在CF患者使用黏液活性药物的一些问题上达成的共识，有助于根据专家经验指导临床医生的日常实践，并为个体患者确定最合适的治疗策略。
Zotero 插件